CD44 and cancer: In the present study, ex vivo experiments demonstrated that mEp-NIR-PIT effectively eradicated cancer cells while sparing T cells and dendritic cells (DCs) in the TME, unlike CD44-NIR-PIT, which reduced these immune cell populations.